Evercore ISI Group maintains NovoCure at Outperform, lowers price target to $20 from $23
Evercore ISI Group kept its Outperform rating on NovoCure but reduced its price target to $20 from $23, a 13% decrease. The new target suggests a 52.6% upside from the Oct 29 closing price of $13.11, according to the firm.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short‑term selling but does not change the company's fundamentals.
Market read
Analyst target changes are a common catalyst for small‑cap biotech price moves.
What to watch
No new clinical data released; the downgrade is purely opinion‑based.
Background
NovoCure is a small‑cap oncology immunotherapy company; analyst coverage influences its price volatility.
Ticker impact
Evercore ISI lowered NovoCure's price target to $20 from $23, a 13% cut.
likely pressure as the market prices in the lower target
Analyst downgrade typically leads to short-term sell pressure, especially for a small‑cap biotech.
Market effects
May weigh on other biotech stocks as analysts tighten targets.
Limited to US biotech sector.
Minimal beyond niche investors.
Counterpoint
Target cut could be overcautious; upside remains if upcoming trial data are positive.
Key entities
- analystEvercore ISI Group
Equity research firm issuing the target cut.
- companyNovoCure
Biotech firm developing immunotherapy treatments.

